$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416132825 Filed on November 09, 2016

Income Statement

Concept	2016 Q3	2016 Q1	2015 Q3
Revenue	$2.686M	$5.195M	$2.947M
YoY Change	-8.86%	320.99%	134.63%
Cost Of Revenue	$1.851M	$1.036M	$1.415M
YoY Change	30.81%	14.6%	107.48%
Gross Profit	$835.0K	$4.159M	$1.532M
YoY Change	-45.5%	1156.5%	166.43%
Gross Profit Margin	31.09%	80.06%	51.99%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$1.267M		$4.172M
YoY Change	-69.64%		16.43%
% of Gross Profit	151.7%		272.35%
Depreciation & Amortization	$165.8K	$180.0K	$160.8K
YoY Change	3.12%	-357.14%	-30.09%
% of Gross Profit	19.86%	4.33%	10.5%
Operating Expenses	$2.040M	$3.588M	$5.299M
YoY Change	-61.5%	-38.01%	14.3%
Operating Profit	-$1.205M	$571.0K	-$3.767M
YoY Change	-68.01%	-110.46%	-7.24%
Interest Expense	$57.38K		$63.82K
YoY Change	-10.1%		-8.92%
% of Operating Profit
Other Income/Expense, Net	$5.443M	$7.408M	$2.086M
YoY Change	160.93%	-924.94%	-79.77%
Pretax Income	$4.238M		-$1.681M
YoY Change	-352.06%		-107.86%
Income Tax	$0.00	-$520.0K	$0.00
% Of Pretax Income	0.0%
Net Earnings	$4.238M	$8.499M	-$1.681M
YoY Change	-352.11%	-233.84%	-126.9%
Net Earnings / Revenue	157.78%	163.6%	-57.04%
Basic Earnings Per Share	$0.03	$0.03	-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	806.9M shares	695.2M shares	665.3M shares
Diluted Shares Outstanding	816.0M shares		823.5M shares

Balance Sheet

Concept	2016 Q3	2016 Q1	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.58M	$11.51M	$9.030M
YoY Change	39.31%	54.29%	18.35%
Cash & Equivalents	$12.58M	$11.51M	$9.031M
Short-Term Investments
Other Short-Term Assets	$300.0K	$380.0K	$300.0K
YoY Change	0.0%	-2.56%	-34.78%
Inventory	$5.640M	$3.294M	$3.353M
Prepaid Expenses
Receivables	$1.150M	$1.530M	$1.416M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.66M	$16.71M	$14.10M
YoY Change	39.48%	35.55%	20.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.352M	$8.111M	$7.555M
YoY Change	10.55%	26.69%	46.12%
Goodwill
YoY Change
Intangibles	$6.418M	$6.412M	$6.400M
YoY Change	0.28%	0.47%
Long-Term Investments	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	-75.0%	25.0%
Other Assets	$390.0K	$437.7K	$649.2K
YoY Change	-39.92%	-45.7%	6.42%
Total Long-Term Assets	$15.21M	$14.96M	$1.960M
YoY Change	676.02%	10.09%	-83.91%
TOTAL ASSETS
Total Short-Term Assets	$19.66M	$16.71M	$14.10M
Total Long-Term Assets	$15.21M	$14.96M	$1.960M
Total Assets	$34.87M	$31.67M	$28.70M
YoY Change	21.5%	22.2%	20.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.280M	$1.804M	$3.610M
YoY Change	-36.85%	-46.67%	34.7%
Accrued Expenses	$1.430M	$555.4K
YoY Change		-9.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$34.68K	$410.0K
YoY Change	-100.0%		-38.81%
Long-Term Debt Due	$410.0K	$308.3K	$470.0K
YoY Change	-12.77%	16.25%	40.32%
Total Short-Term Liabilities	$5.135M	$4.640M	$4.508M
YoY Change	13.91%	-8.46%	18.32%
LONG-TERM LIABILITIES
Long-Term Debt	$1.980M	$2.180M	$2.065M
YoY Change	-4.12%	5.31%	783.13%
Other Long-Term Liabilities	$35.25K	$47.42K	$549.5K
YoY Change	-93.58%	-92.46%	-99.25%
Total Long-Term Liabilities	$7.260M	$15.87M	$11.70M
YoY Change	-37.94%	-22.89%	-84.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.135M	$4.640M	$4.508M
Total Long-Term Liabilities	$7.260M	$15.87M	$11.70M
Total Liabilities	$12.39M	$20.51M	$16.21M
YoY Change	-23.52%	-20.04%	-79.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$137.3M	-$142.7M	-$136.9M
YoY Change	0.28%	0.48%	-34.17%
Common Stock	$160.1M	$109.8M	$116.9M
YoY Change	36.98%	2.13%	-23.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K	$306.8K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	$22.48M	-$33.12M	-$20.36M
YoY Change
Total Liabilities & Shareholders Equity	$34.87M	$31.67M	$28.70M
YoY Change	21.5%	22.2%	20.13%

Cashflow Statement

Concept	2016 Q3	2016 Q1	2015 Q3
OPERATING ACTIVITIES
Net Income	$4.238M	$8.499M	-$1.681M
YoY Change	-352.11%	-233.84%	-126.9%
Depreciation, Depletion And Amortization	$165.8K	$180.0K	$160.8K
YoY Change	3.12%	-357.14%	-30.09%
Cash From Operating Activities	-$2.320M	$600.0K	-$3.480M
YoY Change	-33.33%	-115.58%	-21.44%
INVESTING ACTIVITIES
Capital Expenditures	-$240.0K	-$570.0K	-$700.0K
YoY Change	-65.71%	-5.0%	118.75%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$240.0K	-$570.0K	-$700.0K
YoY Change	-65.71%	-5.0%	84.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.320M	3.370M	1.600M
YoY Change	45.0%	-7.67%	-62.44%
NET CHANGE
Cash From Operating Activities	-2.320M	600.0K	-3.480M
Cash From Investing Activities	-240.0K	-570.0K	-700.0K
Cash From Financing Activities	2.320M	3.370M	1.600M
Net Change In Cash	-240.0K	3.400M	-2.580M
YoY Change	-90.7%	-525.0%	369.09%
FREE CASH FLOW
Cash From Operating Activities	-$2.320M	$600.0K	-$3.480M
Capital Expenditures	-$240.0K	-$570.0K	-$700.0K
Free Cash Flow	-$2.080M	$1.170M	-$2.780M
YoY Change	-25.18%	-136.0%	-32.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142664747	USD
CY2016Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	22475303	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8110721	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6417832	USD
CY2016Q3	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2016Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8351757	USD
CY2016Q1	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	718309	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2279749	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1804429	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5135012	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4640189	USD
CY2016Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	520829	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7259531	USD
CY2016Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15870482	USD
CY2016Q3	us-gaap	Liabilities Liabilities	12394543	USD
CY2016Q1	us-gaap	Liabilities Liabilities	20510671	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	893673	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	711546	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	109137805	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	656141476	shares
CY2016Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2033074	USD
CY2015Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	393312	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	-33122237	USD
	us-gaap	Interest Expense InterestExpense	139257	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34869846	USD
	us-gaap	Interest Expense InterestExpense	126320	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31674149	USD
CY2016Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2016Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	44285715	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	4228968	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	4584932	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	880644	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1371912	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5109612	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5956844	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2611497	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4029246	USD
	us-gaap	Gross Profit GrossProfit	2498115	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2786154	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1560630	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1368562	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	171470	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43376	USD
	us-gaap	Operating Expenses OperatingExpenses	8671963	USD
	us-gaap	Operating Expenses OperatingExpenses	4372261	USD
	us-gaap	Net Income Loss NetIncomeLoss	3050942	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2444663	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	9364047	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	7896849	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9224790	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7776785	USD
	us-gaap	Net Income Loss NetIncomeLoss	5332122	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	26046408	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	765055707	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4408109	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6411799	USD
CY2016Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1576867	USD
CY2016Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1654777	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	35251	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47422	USD
CY2016Q3	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	2471718	USD
CY2016Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	10368567	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2772223	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3278887	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1429944	USD
CY2016Q3	us-gaap	Loans Payable Current LoansPayableCurrent	341164	USD
CY2016Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	403472	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	159221096	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137332625	USD
	us-gaap	Gross Profit GrossProfit	1927598	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6614063	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3050942	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5332122	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	1357167	USD
CY2016Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	652624	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2946507	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2685698	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	1850769	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1204599	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	63824	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	4238098	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1681376	USD
CY2016Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	22857143	USD
CY2015Q3	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-5071406	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1681376	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3147	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27095241	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6752782	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	806868491	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	665330431	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	816026737	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	823495279	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	174169	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	57377	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	20714286	USD
CY2015Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	2553195	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3831163	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1258829	USD
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	158164848	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	158164848	shares
CY2016Q3	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.18
CY2016Q1	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.31
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4238098	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6256	USD
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	321311	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	1232950	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	187920	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-718309	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-171362	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	834929	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4172419	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1266712	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	881566	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	667047	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	80992	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84785	USD
CY2015Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	164340	USD
CY2016Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20984	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	5299317	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2039528	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3767339	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5442697	USD
CY2015Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	2149787	USD
CY2016Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	5496927	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2085963	USD
	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	1273678	USD
	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	0	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	17669	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4531774	USD
	eltp	Stock Issued During Period Value Payment Of Employee Salaries StockIssuedDuringPeriodValuePaymentOfEmployeeSalaries	13751	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	345419	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325799	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7896849	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9364047	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	586167	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	171470	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-384793	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-147650	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2341806	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-75889	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-242721	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-960122	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-506664	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	4660000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3081435	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1588019	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-519392	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1423526	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	513359	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1405633	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6033	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17893	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1277678	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2328255	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4668331	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4578453	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1067504	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1566908	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7464180	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9031088	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	116962	USD
	us-gaap	Interest Paid InterestPaid	120508	USD
	us-gaap	Interest Paid InterestPaid	110372	USD
	us-gaap	Depreciation Depreciation	318711	USD
	us-gaap	Depreciation Depreciation	338330	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2564727	USD
CY2015Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-2921619	USD
CY2015	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	5000000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	10721214	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	222784	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4531774	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	148582	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	17669	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2780142	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6313105	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5316335	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.1
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.46
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2016Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5118117	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2845247	USD
CY2016Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	221935	USD
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	295483	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	225698	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7064730	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6726401	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	43329	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	41994	USD
CY2016Q3	us-gaap	Deferred Revenue DeferredRevenue	3785556	USD
CY2015Q1	eltp	Warrants Outstanding WarrantsOutstanding	89870034	shares
CY2016Q1	eltp	Warrants Outstanding WarrantsOutstanding	41586066	shares
CY2016Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q3	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q3	eltp	Warrants Outstanding WarrantsOutstanding	21127218	shares
CY2015Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	48283968	shares
	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	20458848	shares
	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	7896849	USD
CY2016Q3	eltp	Common Stock Traded Percent CommonStockTradedPercent	0.3	pure
CY2016Q3	eltp	Common Stock Weighted Average Price Percent CommonStockWeightedAveragePricePercent	0.97	pure
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	624917	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7609667	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	870000	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7539667	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	900000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	904409	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	383330	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	379400	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ELTP
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	905662789	shares
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7064730	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6726407	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	395.758	shares
CY2016Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	495.758	shares
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	117095	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	185143	USD
CY2016Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2016Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100	shares
CY2016Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	893670036	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	893570036	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	711544352	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	711444352	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	-13018	USD
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	-10991	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	847	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	798	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	66006	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	65794	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	220000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	23571429	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 &amp; 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
CY2016Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	28354070	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	28611135	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9158246	shares
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9158246	shares
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
CY2016Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2016	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	129913	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	333363	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	23571429	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15416487	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14837122	USD
CY2016Q3	us-gaap	Depreciation Depreciation	165815	USD
CY2015Q3	us-gaap	Depreciation Depreciation	160795	USD
CY2016Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6411799	USD
	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	6033	USD
CY2016Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6381774	USD
CY2016	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	30025	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	21042	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	20353	USD
CY2016Q1	us-gaap	Deferred Revenue DeferredRevenue	4292220	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 10. COMMITMENTS AND CONTINGENCIES</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business.  The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated.  If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements.  Contingencies are inherently unpredictable and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Legal Proceedings</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Arbitration with Precision Dose, Inc.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 9, 2014, Precision Dose Inc., the parent company of TAGI Pharmaceuticals, Inc., commenced an arbitration against the Company alleging that the Company failed to properly supply, price and satisfy gross profit minimums regarding Phentermine 37.5mg tablets, as required by the parties’ agreements. Elite denied Precision Dose’s allegations and has counterclaimed that Precision Dose is no longer entitled to exclusivity rights with respect to Phentermine 37.5mg tablets, and is responsible for certain costs, expenses, price increases and lost profits relating to Phentermine 37.5mg tablets and the parties’ agreements. The parties have reached agreement in settlement of these issues, with Precision Dose agreeing to pay certain amounts to the Company in exchange for Elite agreeing to restore exclusivity rights with respect to Phentermine 37.5mg tablets, subject to certain defined conditions. Both parties have been complying with the agreed settlement terms and the Company has notified the Arbitrator of this settlement, requesting the issuance of proceeding termination documents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Due to the agreements reached and adhered to with regards to this issue, the Company has determined that no contingency loss needs to be recorded.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Operating Leases 135 Ludlow Ave.</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The 135 Ludlow Ave. lease is for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000</font> square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000</font> square feet of floor space in the building (“135 Ludlow Ave. modified lease”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. modified lease, includes an initial term, which expires on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company’s manufacturing resources are in progress.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the three-month ended September 30, 2016 and 2015 was $45,213 and $45,214, respectively and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,426</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,427</font> for the six months ended September 30, 2016 and 2015 respectively. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations. Deferred rent as of September 30, 2016 and March 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,505</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,528</font>, respectively and recorded as a component of other long-term liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, <i>Asset Retirement and Environmental Obligations Asset Retirement Obligations</i>. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of September 30, 2016 and March 31, 2016, the Company had a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,743</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,895</font>, respectively and recorded as a component of other long-term liabilities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.19	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.21	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.19	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.021	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
	eltp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0	pure
CY2016	eltp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.027	pure
	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	317634	USD
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
CY2016Q3	eltp	Unamortization Of Bond UnamortizationOfBond	197311	USD
CY2016Q1	eltp	Unamortization Of Bond UnamortizationOfBond	204401	USD
CY2016Q3	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2016Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2016Q3	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	157142	USD
CY2016Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	150052	USD

Files In Submission

Name	View Source	Status
0001144204-16-132825-index-headers.html	Edgar Link	pending
0001144204-16-132825-index.html	Edgar Link	pending
0001144204-16-132825.txt	Edgar Link	pending
0001144204-16-132825-xbrl.zip	Edgar Link	pending
eltp-20160930.xml	Edgar Link	completed
eltp-20160930.xsd	Edgar Link	pending
eltp-20160930_cal.xml	Edgar Link	unprocessable
eltp-20160930_def.xml	Edgar Link	unprocessable
eltp-20160930_lab.xml	Edgar Link	unprocessable
eltp-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pg1img1_ex10-45.jpg	Edgar Link	pending
pg1img1_ex10-46.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v451838_10q.htm	Edgar Link	pending
v451838_ex10-44.htm	Edgar Link	pending
v451838_ex10-45.htm	Edgar Link	pending
v451838_ex10-46.htm	Edgar Link	pending
v451838_ex31-1.htm	Edgar Link	pending
v451838_ex31-2.htm	Edgar Link	pending
v451838_ex32-1.htm	Edgar Link	pending
v451838_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q3 Form 10-Q Financial Statement

#000114420416132825 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q3 Form 10-Q Financial Statement

#000114420416132825 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp